| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(9 years from now) | |
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(15 years from now) | |
| US11628162 | INCYTE CORP | Methods of treating cancer with an FGFR inhibitor |
Aug, 2040
(16 years from now) | |
Pemazyre is owned by Incyte Corp.
Pemazyre contains Pemigatinib.
Pemazyre has a total of 4 drug patents out of which 0 drug patents have expired.
Pemazyre was authorised for market use on 17 April, 2020.
Pemazyre is available in tablet;oral dosage forms.
Pemazyre can be used as treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg, treatment of relapsed or refractory myeloid/lymphoid neoplasms with fgfr1 rearrangement by administering pemigatinib while avoiding the concomitant use of strong and moderate cyp3a inhibitors, for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement.
Drug patent challenges can be filed against Pemazyre from 17 April, 2024.
The generics of Pemazyre are possible to be released after 30 August, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
| New Indication(I-899) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...
Dosage: TABLET;ORAL
PEMAZYRE family patents
